LobbyingMetabolic Syndrome Insulin Infusion Holdings lobbying by quarter
Metabolic Syndrome Insulin Infusion Holdings's latest lobbying report covers Q2 2026, at $15K. The four quarters Q4 2025–Q3 2026 total $45K. Its first report covers Q3 2024; the issues it reports most are Accounting and Health Issues.
Metabolic Syndrome Insulin Infusion Holdings
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $45K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2024 | $15K | 1 |
| Q4 2024 | $15K | 1 |
| Q1 2025 | $15K | 1 |
| Q2 2025 | $15K | 1 |
| Q3 2025 | $15K | 1 |
| Q4 2025 | $15K | 1 |
| Q1 2026 | $15K | 1 |
| Q2 2026 | $15K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Accounting$60K · 8 reports
- Health issues$60K · 8 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Executive Office of the President (EOP)8 reports
- HOUSE OF REPRESENTATIVES8 reports
- SENATE8 reports
Firms it paid
| Firm | ||
|---|---|---|
| Bell & Lindsay | $120K | 8 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARK F LINDSAY | U.S House Staff | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Bell & Lindsay | $15K |
| 04/20for Q1 | Bell & Lindsay | $15K |
| 01/20for Q4 2025 | Bell & Lindsay | $15K |
| 25/10/20for Q3 2025 | Bell & Lindsay | $15K |
| 25/07/21for Q2 2025 | Bell & Lindsay | $15K |
| 25/04/21for Q1 2025 | Bell & Lindsay | $15K |
| 25/01/21for Q4 2024 | Bell & Lindsay | $15K |
| 24/10/21for Q3 2024 | Bell & Lindsay | $15K |
| 24/07/19for Q3 2024 | Bell & Lindsay | $15K |
| 24/07/08for Q3 2024 | Bell & Lindsay | Under $5,000 |